PS5-09-30: A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancer
Year: 2026
Type: article
Source: Clinical Cancer Research
Authors: F. Yan, T. Mukohara, Y. Park, S. Im, G. Kim, T. Yamashita, D. Sommerhalder, R. Layman, E. Hamilton, S. Kim, F. Hara, S. Wang, J. Chien, J. Kim, T. Clay, R. Joshi, Y. Chae, C. Oakman, B. Holbrook, B. Dong, Y. Cheng, H. Li, J. Yang, S. Kent, L. Liu, K. Kowalski, S. Badhrinarayanan, A. Skoura, L. Howie, P. Lorusso
Institutions: National Cancer Center Hospital East, Samsung Medical Center, Sungkyunkwan University, Seoul National University, Seoul National University Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Kanagawa Cancer Center, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Asan Medical Center, University of Ulsan, Aichi Cancer Center, Sun Yat-sen University Cancer Center, University of California, San Francisco, Seoul National University Bundang Hospital, St John of God Subiaco Hospital, Kyungpook National University, Kyungpook National University Chilgok Hospital, Western Health, Sunshine Hospital, St. Elizabeth Healthcare, University of Louisville, University of Louisville Hospital, Jilin Province Tumor Hospital, Peking University Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Pfizer (United States), Yale University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129724079
FWCI:
Cites:
Cited by:
Related to: